Last reviewed · How we verify
Aripiprazole tablets
Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors, which stabilizes dopamine and serotonin neurotransmission in the brain.
Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors, which stabilizes dopamine and serotonin neurotransmission in the brain. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Aripiprazole tablets |
|---|---|
| Sponsor | Chengdu Kanghong Pharmaceutical Group Co., Ltd. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor (partial agonist); Serotonin 5-HT1A receptor (partial agonist); Serotonin 5-HT2A receptor (antagonist) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
Aripiprazole differs from typical antipsychotics by acting as a partial agonist rather than a full antagonist at dopamine D2 receptors. This mechanism allows it to reduce dopamine activity when it is excessive (in psychotic symptoms) while maintaining baseline dopamine function, potentially reducing extrapyramidal side effects. Its additional activity at serotonin receptors contributes to its efficacy in treating both positive and negative symptoms of psychosis and mood disorders.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute manic or mixed episodes)
- Major depressive disorder (adjunctive treatment)
- Autism spectrum disorder (irritability)
Common side effects
- Akathisia
- Headache
- Anxiety
- Insomnia
- Nausea
- Weight gain
- Tremor
- Sedation
Key clinical trials
- Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia (PHASE3)
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia (PHASE3)
- Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis (PHASE1)
- RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT) (PHASE4)
- Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (PHASE4)
- A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia (PHASE3)
- A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aripiprazole tablets CI brief — competitive landscape report
- Aripiprazole tablets updates RSS · CI watch RSS
- Chengdu Kanghong Pharmaceutical Group Co., Ltd. portfolio CI